SP 420

Drug Profile

SP 420

Alternative Names: SP-420

Latest Information Update: 19 Apr 2016

Price : $50

At a glance

  • Originator University of Florida
  • Developer Sideris Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Iron chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Iron overload

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Oct 2014 Phase-I clinical trials in Iron overload in USA (PO)
  • 22 Oct 2013 Preclinical trials in Iron overload in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top